# Modulatory effects of CeO2 nanoparticles on bleomycin-induced active pulmonary disease processes in animal and human airway epithelium models

**Authors:** Chang Guo, Alison Buckley, Sarah Robertson, Adam Laycock, Xianjin Cui, Eugenia Valsami-Jones, Tim Gant, Martin O. Leonard, Rachel Smith

PMC · DOI: 10.1186/s12989-026-00658-9 · 2026-01-16

## TL;DR

This study explores how cerium oxide nanoparticles affect lung injury in animal and human models, showing both protective and harmful effects depending on timing.

## Contribution

The study demonstrates that CeO2NPs can modulate lung injury responses during active disease processes, emphasizing the importance of exposure timing.

## Key findings

- CeO2NP exposure reduced fibrotic staining and inflammatory gene expression in bleomycin-treated rats.
- In vitro models showed CeO2NPs modulated some bleomycin-induced responses but lacked whole-body complexity.
- Findings highlight the context-dependent effects of CeO2NPs in pre-existing lung injury.

## Abstract

Understanding the impacts of inhaled insoluble nanomaterials as they are encountered in the environment and workplace, in injured lungs remains limited, particularly with respect to their role in the progression or mitigation of lung pathology. While some studies suggest potential protective effects of cerium(IV) oxide nanoparticles (CeO2NPs) under certain conditions, their influence during active disease processes is unclear. This study builds on prior work to investigate the effects of CeO2NP aerosols on bleomycin-induced pulmonary injury and active disease processes.

To establish conditions of active pulmonary disease processes, bleomycin was used in both animal and airway epithelium models. Male Sprague-Dawley rats were intratracheally instilled with bleomycin or saline (control) followed by nose-only inhalation exposure to CeO2NP aerosols (diameter of ~ 43 nm) or control for 3 h per day for 4 days per week for one or two weeks. At three days postexposure, the animals were sacrificed for analysis of bronchoalveolar lavage (BAL) fluid, lung histopathology and global mRNA expression. Comparative in vitro studies were conducted to investigate biological responses at the cellular level, using 3D human small airway epithelium cultures (SmallAir™) exposed to CeO2NP aerosols (with a diameter of ~ 86 nm) at the air-liquid-interface at deposition doses comparable to those received in vivo in the small airway.

In vivo, bleomycin treatment resulted in an increase in total BAL cells and fibrotic staining, and significant induction of inflammatory and oxidative stress, as shown by mRNA sequencing analysis. One week of exposure to CeO2NPs modified these responses by attenuating fibrotic staining and reducing the expression of genes associated with lung function, inflammation and epithelial-mesenchymal transition (EMT). In vitro, CeO2NP exposure modulated some bleomycin-induced cellular responses, although these models do not fully capture the complexity of whole body and tissue systems, highlighting limitations and considerations for future in vitro exposure studies.

In this study, inhaled CeO2NPs modulated lung injury responses in the context of active disease, with both potential protective effects and adverse outcomes. These findings demonstrate that the timing of CeO2NP exposure relative to disease progression is critical and highlight the need for hazard assessment frameworks to consider context-dependent effects, particularly in the presence of pre-existing lung injury.

The online version contains supplementary material available at 10.1186/s12989-026-00658-9.

## Linked entities

- **Chemicals:** bleomycin (PubChem CID 5360373)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** Mir146a (microRNA 146a) [NCBI Gene 100314241] {aka rno-mir-146a}, Fn1 (fibronectin 1) [NCBI Gene 25661] {aka FIBNEC, fn-1}, Slc7a11 (solute carrier family 7 member 11) [NCBI Gene 310392], Fndc1 (fibronectin type III domain containing 1) [NCBI Gene 308099], Muc5ac (mucin 5AC, oligomeric mucus/gel-forming) [NCBI Gene 682837] {aka AABR07006032.1}, Cxcl1 (C-X-C motif chemokine ligand 1) [NCBI Gene 81503] {aka CINC-1, Gro1}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 59086] {aka Tgfb}, Col12a1 (collagen type XII alpha 1 chain) [NCBI Gene 25683], P4hb (prolyl 4-hydroxylase subunit beta) [NCBI Gene 25506] {aka PDI, PDIR}, HPRT1 (hypoxanthine phosphoribosyltransferase 1) [NCBI Gene 3251] {aka HGPRT, HPRT}, Tgfb3 (transforming growth factor, beta 3) [NCBI Gene 25717] {aka TGF-B3}, Hmox1 (heme oxygenase 1) [NCBI Gene 24451] {aka HEOXG, Heox, Hmox, Ho-1, Ho1, hsp32}, Lcn2 (lipocalin 2) [NCBI Gene 170496] {aka Sip24}, Txnrd1 (thioredoxin reductase 1) [NCBI Gene 58819] {aka Tr}, Spp1 (secreted phosphoprotein 1) [NCBI Gene 25353] {aka OSP}, Il6 (interleukin 6) [NCBI Gene 24498] {aka ILg6, Ifnb2}, Timp1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 116510] {aka TIMP-1, Timp}, Tlr4 (toll-like receptor 4) [NCBI Gene 29260]
- **Diseases:** fibrotic lung (MESH:D008171), acute (MESH:D000208), acute lung injury (MESH:D055371), Inflammatory (MESH:D007249), GSD (MESH:D016098), lung inflammation (MESH:D011014), overdose (MESH:D062787), MPPD (MESH:D009104), burn (MESH:D002056), chronic liver disease (MESH:D008107), ophthalmic diseases (MESH:C535922), cardiovascular diseases (MESH:D002318), impaired lung function (MESH:D003072), fibrotic disease (MESH:D004194), COPD (MESH:D029424), CMD (MESH:C565145), diabetes (MESH:D003920), oedema (MESH:C536897), Alzheimer's disease (MESH:D000544), neurological disorders (MESH:D009461), asthma (MESH:D001249), Cytotoxicity (MESH:D064420), AE-ALI (MESH:D004618), cancer (MESH:D009369), type II alveolar hyperplasia (MESH:C538236), fibrosis (MESH:D005355), type II (MESH:D006938), alveolar epithelial hyperplasia (MESH:D017573), neuroinflammation (MESH:D000090862), hyperplasia (MESH:D006965), interstitial pulmonary diseases (MESH:D017563), Pulmonary Fibrosis (MESH:D011658), inflammatory lung injury (MESH:D055370), IPF (MESH:D054990), tissue injury (MESH:D017695)
- **Chemicals:** isoflurane (MESH:D007530), Saline (MESH:D012965), H2O (MESH:D014867), LPS (MESH:D008070), DA (MESH:C025953), CM (MESH:D003476), Haematoxylin (MESH:D006416), Silver (MESH:D012834), pentobarbital (MESH:D010424), PBS (MESH:D007854), paraffin (MESH:D010232), CO2 (MESH:D002245), copper (MESH:D003300), ROS (MESH:D017382), H&amp;E (MESH:D006371), Nickel oxide (MESH:C028007), oxygen (MESH:D010100), eosin (MESH:D004801), paraformaldehyde (MESH:C003043), carbon (MESH:D002244), pyrimidine (MESH:C030986), CeO 2 (MESH:C030583), iron (MESH:D007501), SiO2 (MESH:D012822), AgNPs (-), AE (MESH:C538178), cerium (MESH:D002563), ZnO (MESH:D015034), nitrogen (MESH:D009584), nitroxide (MESH:C039900), TiO2 (MESH:C009495), imidazole (MESH:C029899), Bleomycin (MESH:D001761)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116], Streptomyces verticillus (species) [taxon 29309]
- **Cell lines:** A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12829198/full.md

---
Source: https://tomesphere.com/paper/PMC12829198